Smith D, Schmid E, Jones B. Do drug metabolism and pharmacokinetic departments
make any contribution to drug discovery? Clin Pharmacokinet 2002;41:1005–
1019.
Smith DA, Obach RS. Seeing through the mist: abundance versus percentage.
Commentary on metabolites in safety testing. Drug Metab Dispos 2005;33:
1409–1417.
Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and
prediction ofin vivometabolic clearance. J Pharmacol Exp Ther 2002;301:382–390.
Soldner A, Spahn-Langguth H, Palm D, Mutschler E. A radioreceptor assay for the
analysis of AT1-receptor antagonists. Correlation with complementary LC data
reveals a potential contribution of active metabolites. J Pharm Biomed Anal
1998;17:111–124.
Taskinen J, Ethell BT, Pihlavisto P, Hood AM, Burchell B, Coughtrie MW.
Conjugation of catechols by recombinant human sulfotransferases, UDP-
glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-
conjugation relationships and predictive models. Drug Metab Dispos 2003;31:
1187–1197.
Thompson TN. Optimization of metabolic stability as a goal of modern drug design.
Med Res Rev 2001;21:412–449.
Tran TH, von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS,
Harmatz JS, Greenblatt DJ. Microsomal protein concentration modifies the
apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 2002;
30:1441–1445.
Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug
reactions. Drug Discov Today 2003;8:832–837.
van de Waterbeemd H, Gifford E. ADMETin silicomodelling: towards prediction
paradise? Nat Rev Drug Discov 2003;2:192–204.
van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz
EJ, Davis, HR Jr. In vivometabolism-based discovery of a potent cholesterol
absorption inhibitor, SCH58235, in the rat and rhesus monkey through the
identification of the active metabolites of S CH48461. J Pharmacol Exp Ther
1997;283:157–163.
Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced
idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325–361.
Ward DP, Trevor AJ, Kalir A, Adams JD, Baillie TA, Castagnoli N Jr. Metabolism of
phencyclidine. The role of iminium ion formation in covalent binding to rabbit
microsomal protein. Drug Metab Dispos 1982;10:690–695.
Watt AP, Mortishire-Smith RJ, Gerhard U, Thomas SR. Metabolite identification in
drug discovery. Curr Opin Drug Discov Devel 2003;6:57–65.
White IN, De Matteis F, Gibbs AH, Lim CK, Wolf CR, Henderson C, Smith LL.
Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and
the forms of cytochrome P450 involved. Biochem Pharmacol 1995;49:1035–1042.
White, RE. High-throughput screening in drug metabolism and pharmacokinetic
support of drug discovery. Annu Rev Pharmacol Toxicol 2000;40:133–157.
Yamamoto T, Itoga H, Kohno Y, Nagata K, Yamazoe Y. Prediction of oral clearance
from in vitro metabolic data using recombinant CYPs: comparison among
REFERENCES 259